Pfizer has entered an agreement to acquire InnoPharma, Inc., a privately-held pharmaceutical development company, for $225 million in cash upfront, and as much as $135 million of contingent milestone payments. The transaction, subject to U.S. regulatory approval, is expected to occur during 3Q14. InnoPharma based in Piscataway, NJ, has capabilities in complex injectable delivery forms, including pens and depot injectables, and has been working expand into new dosage forms, including oral suspen...